Lenalidomide

来那度胺

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameLenalidomide
Drug Alias NameLenalidomidum那利度胺雷利度胺Lenalidomida来拉度胺 +[18] 
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Molecular Glue
Mechanisms of ActionCereblon modulatorsDNA-binding protein Ikaros degradersZinc finger protein Aiolos degraders +[4] 
TargetsCereblonDNA-binding protein IkarosZinc finger protein Aiolos +[4] 
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursAngioimmunoblastic T-cell Lymphoma +[112] 
Global Approved IndicationsMyelodysplastic SyndromesMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2005/12/27
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstitutePenn Pharmaceuticals Services LtdBristol Myers Squibb Srlcompany +[16] 
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)The University Of California DavisWeill Medical College of Cornell University +[39] 
Active IndicationsCognitive DysfunctionNerve DegenerationPlaque, Amyloid +[21] 
Inactive IndicationsCNS Embryonal TumorSolid tumoursAngioimmunoblastic T-cell Lymphoma +[91] 

Other Information

ATC CodeL04AX04
Related LinksWikipediaDrugBankKEGG